D N Slatkin
Overview
Explore the profile of D N Slatkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1124
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hainfeld J, OConnor M, Dilmanian F, Slatkin D, Adams D, Smilowitz H
Br J Radiol
. 2010 Nov;
84(1002):526-33.
PMID: 21081567
Objectives: Gold nanoparticles are of interest as potential in vivo diagnostic and therapeutic agents, as X-ray contrast agents, drug delivery vehicles and radiation enhancers. The aim of this study was...
2.
Slatkin D, Blattmann H, Wagner H, Glotzer M, Laissue J
Dev Med Child Neurol
. 2008 Nov;
51(2):163.
PMID: 19018844
No abstract available.
3.
Laissue J, Blattmann H, Wagner H, Grotzer M, Slatkin D
Dev Med Child Neurol
. 2007 Jul;
49(8):577-81.
PMID: 17635201
Microbeam radiation therapy (MRT), a form of experimental radiosurgery of tumours using multiple parallel, planar, micrometres-wide, synchrotron-generated X-ray beams ('microbeams'), can safely deliver radiation doses to contiguous normal animal tissues...
4.
Smilowitz H, Blattmann H, Brauer-Krisch E, Bravin A, Di Michiel M, Gebbers J, et al.
J Neurooncol
. 2006 Apr;
78(2):135-43.
PMID: 16598429
Purpose: Microbeam radiation therapy (MRT), a novel experimental radiosurgery that largely spares the developing CNS and other normal tissues, is tolerated well by developing animals and palliates advanced 9LGS tumors....
5.
Hainfeld J, Slatkin D, Focella T, Smilowitz H
Br J Radiol
. 2006 Feb;
79(939):248-53.
PMID: 16498039
There have been few fundamental improvements in clinical X-ray contrast agents in more than 25 years, and the chemical platform of tri-iodobenzene has not changed. Current agents impose serious limitations...
6.
Miura M, Blattmann H, Brauer-Krisch E, Bravin A, Hanson A, Nawrocky M, et al.
Br J Radiol
. 2006 Jan;
79(937):71-5.
PMID: 16421408
Microbeam radiosurgery (MBRS), also referred to as microbeam radiation therapy (MRT), was tested at the European Synchrotron Radiation Facility (ESRF). The left tibiofibular thigh of a mouse bearing a subcutaneously...
7.
Miura M, Morris G, Micca P, Nawrocky M, Makar M, Cook S, et al.
Br J Radiol
. 2004 Jul;
77(919):573-80.
PMID: 15238404
Copper tetracarboranyltetraphenylporphyrin (CuTCPH) is a minimally toxic carborane-containing porphyrin that has safely delivered high concentrations of boron for experimental boron neutron capture therapy (BNCT). Copper octabromotetracarboranylphenylporphyrin (CuTCPBr), synthesized by bromination...
8.
Smilowitz H, Coderre J, Nawrocky M, Tu W, Pinkerton A, Jahng G, et al.
J Neurooncol
. 2002 Jul;
57(1):9-18.
PMID: 12125969
Rats with advanced, imminently lethal, approximately 4 mm diameter, left-sided intracerebral 9L gliosarcoma (9LGS), a well characterized malignant tumor with some similarities to human high-grade astrocytomas, were used as a...
9.
Miura M, JOEL D, Smilowitz H, Nawrocky M, Micca P, Hoch D, et al.
J Neurooncol
. 2001 Aug;
52(2):111-7.
PMID: 11508810
The biodistributions of carborane-containing copper porphyrins, CuTCP and CuTCPH, have been studied previously in mice bearing subcutaneously implanted mammary carcinomas. We now report biodistributions of those porphyrins in Fischer 344...
10.
Miura M, Morris G, Micca P, Lombardo D, Youngs K, Kalef-Ezra J, et al.
Radiat Res
. 2001 Mar;
155(4):603-10.
PMID: 11260662
The first control of a malignant tumor in vivo by porphyrin- mediated boron neutron capture therapy (BNCT) is described. In mice bearing implanted EMT-6 mammary carcinomas, boron uptake using a...